FREDERICK, Md., Nov. 24, 2008 (GLOBE NEWSWIRE) -- BioElectronics Corp. (Pink Sheets:BIEL), the maker of ActiPatch(tm), the drug free anti-inflammatory patch with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced that Emerging Growth Research, LLP has issued a Buy recommendation on the company's shares through a new research report on the company. The report, which places a 12-month target price of $0.20 on the company's shares, outlines the research firm's belief that the Company's sales are aggressively ramping and that positive clinical data is expected over the next few months. The report can be viewed online at www.wallstreetreportonline.com.
Andrew Whelan, CEO and President of BioElectronics Corp., commented, "We are very pleased to have received such a positive rating in this research report. The management team at BioElectronics is very excited about the positive developments taking place at the company, especially relating to our international distribution. Over the past few months shipments to our international distributors have substantially increased. We believe this is a trend that is likely to continue allowing us to report record revenue levels over the coming quarters. We continue to believe the future is very bright for our company and its shareholders."
About BioElectronics Corporation
BioElectronics Corporation is the maker of the ActiPatch(tm). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. For more information please see www.bioelectronicscorp.com
Safe Harbor Statement
This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.